Long Lasting Response of Trabectedin in Patient With Gastric Leiomyosarcoma With Liver Metastasis: an Update to Previous Report | Zendy

Sameer Rastogi | Zendy; Kaushal Kalra | Zendy; Parisa Manasa | Zendy; Monali Rajawat | Zendy; Varshil Mehta | Zendy

Open Access

Long Lasting Response of Trabectedin in Patient With Gastric Leiomyosarcoma With Liver Metastasis: an Update to Previous Report

Author(s) -

Sameer Rastogi,

Kaushal Kalra,

Parisa Manasa,

Monali Rajawat,

Varshil Mehta

Publication year - 2019

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.2144/fsoa-2019-0085

Subject(s) - trabectedin , medicine , pazopanib , gemcitabine , leiomyosarcoma , oncology , epothilones , docetaxel , metastasis , malignancy , eribulin , metastatic breast cancer , cancer , surgery , sarcoma , breast cancer , pathology , soft tissue sarcoma , chemistry , sunitinib , combinatorial chemistry

Leiomyosarcoma of the stomach is an extremely rare malignancy for which treatment in advanced disease is hardly reported. Here, we report a case of a 48-year-old man with metastatic gastric Leiomyosarcoma who had previously received a combination of gemcitabine and docetaxel followed by pazopanib after detection of metastasis. The patient was started on trabectedin as per protocol and had disease control continuing for 17 cycles of trabectedin. His quality of life and absence of significant toxicities highlight the noncumulative nature of trabectedin and potential benefit in responding cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research